Evidence map›Paper›PMID 41312559›Full record

ArticleCanadian liver journal2025

Post-liver transplant mortality in Canada: A retrospective analysis and quality assurance study in British Columbia.

Nawaf T Aboalfaraj, Sedrah K Talab, Alexander R Hemy, Rana K Talab, Trana Hussaini, Daljeet Chahal, Vladimir Marquez, Benjamin Cox, Eric M Yoshida

Abstract read
In one paragraph

Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nawaf T AboalfarajDepartment of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Sedrah K TalabDepartment of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.
Alexander R HemyDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Rana K TalabDepartment of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Trana HussainiFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Daljeet ChahalDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Vladimir MarquezDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Benjamin CoxDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Eric M YoshidaDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liver transplantation is a life-saving treatment for end-stage liver disease, significantly improving survival. In Canada, the number of liver transplants has increased, with British Columbia performing 107 transplants in 2023. One-year survival rates have risen from 74.8% in 1990 to 93.2% in 2021 due to advancements in surgical and immunosuppressive methods. However, long-term survival remains suboptimal, with malignancy, graft failure, and cardiovascular disease being key contributors to mortality. This study analyzed causes of mortality among liver transplant recipients in British Columbia to identify strategies for improving outcomes. Methods: This retrospective study included 314 deceased liver transplant recipients (age ≥18 years) in British Columbia between 2013 and 2023, using the BC Transplant database. Statistical analyses included descriptive statistics, Kruskal-Wallis survival analysis, and linear regression, with significance set at Results: Malignancy was the leading cause of death (24.8%), followed by unknown causes (19.4%) and multi-organ failure (13.1%). One-year survival rates varied significantly by cause of death ( Conclusions: Malignancy remains the most frequent cause of death post-transplant, requiring enhanced surveillance. The significant variability in 1-year survival by cause of death highlights the need for tailored interventions, particularly to reduce sepsis-related mortality. Improved documentation of unknown causes is critical to optimizing long-term strategies.

Indexed as

allograftlivermortalityrejectionre-transplanttransplant

Identifiers

PMID41312559
PMCPMC12657010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.